79 results
8-K
EX-99
ATOS
Atossa Therapeutics Inc
17 May 18
Atossa Genetics Announces First Quarter 2018 Financial Results
12:16pm
., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Stockholm, Sweden had been appointed as Scientific
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
27 Jun 19
Regulation FD Disclosure
12:48pm
Endoxifen was led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 Sep 18
Atossa Genetics Announces Preliminary Results from
12:00am
by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Stockholm
8-K
EX-99.2
v2x3v
4 Oct 13
Other Events
12:00am
FWP
ak72d3ye
16 May 18
Free writing prospectus
2:39pm
424B3
hznc09nvf2 uo
19 Apr 13
Prospectus supplement
12:00am
DEF 14A
kr1q4o0xp2t 30b
15 Apr 13
Definitive proxy
12:00am
8-K
EX-1.1
3rf626v
10 Feb 20
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
eksim5
25 Sep 20
Entry into a Material Definitive Agreement
5:00pm